Justin M. Balko
Vanderbilt University Medical Center
232 Papers
531 Citations
Justin M. Balko is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 54, co-authored 172 publications. Previous affiliations of Justin M. Balko include The Breast Cancer Research Foundation & Vanderbilt University.
Chat about Author
Papers
Triple-Negative Breast Cancer: Breast Tumors With an Identity Crisis.
TL;DR: In this paper, the authors explore the molecular subtypes of triple negative breast cancer and their distinct characteristics, as well as highlight the molecular features and potential "drivers" that have been identified as promising targets for new treatment strategies.
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Na Luo,Na Luo,Luigi Formisano,Paula I. Gonzalez-Ericsson,Violeta Sanchez,Phillip T. Dean,Susan R. Opalenik,Melinda E. Sanders,Rebecca S. Cook,Carlos L. Arteaga,Douglas B. Johnson,Justin M. Balko +11 more
TL;DR: Amplification of JAK/STAT signaling in tumor cells through genetic inhibition of the negative regulator PTPN2 potentiated IFN-γ response in vitro and in vivo, and may be a target to enhance immunotherapy efficacy.
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression or signaling
Christian D. Young,Adam D. Pfefferle,Philip Owens,Maria G. Kuba,Brent N. Rexer,Justin M. Balko,Violeta Sanchez,Hailing Cheng,Charles M. Perou,Jean J. Zhao,Rebecca S. Cook,Carlos L. Arteaga +11 more
TL;DR: Encouragingly, simultaneous blockade of p110α and ErbB RTKs results in superior inhibition of PI3K and mammary tumor growth, suggesting a rational therapeutic combination against breast cancers harboring PIK3CA activating mutations.
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
David B. Page,Harry D. Bear,Sangeetha Prabhakaran,Margaret E. Gatti-Mays,Alexandra Thomas,Erin F. Cobain,Heather L. McArthur,Justin M. Balko,Sofia R. Gameiro,Rita Nanda,James L. Gulley,Kevin Kalinsky,Julia White,Jennifer K. Litton,Steven J. Chmura,Mei Yin C. Polley,Benjamin G. Vincent,David Cescon,Mary L. Disis,Joseph A. Sparano,Elizabeth A. Mittendorf,Sylvia Adams +21 more
- 08 Oct 2019
TL;DR: Preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer are summarized, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression.
Derek A. Franklin,Jamaal L. James,Margaret L Axelrod,Justin M. Balko +3 more
- 25 Apr 2020
TL;DR: Findings suggest that MAPK signaling and STAT activation are inversely related in both mouse and human mammary tumors and supports further study of MEKi to increase STAT signaling and potentially, immunotherapy responses through increased MHC-I and PD-L1 expression.